Sustained Weight Loss Results
Tirzepatide's dual-receptor mechanism produces superior weight loss compared to single-action GLP-1 agents. Clients typically see 1–2 lbs per week loss when combined with caloric deficit and lifestyle changes.
Weight Loss Therapy
Tirzepatide is a dual-action GLP-1 and GIP receptor agonist proven to deliver significant weight loss results. Vivere Drip Therapy offers prescription tirzepatide injections with medical oversight and personalized dosing protocols.
Book a Session →22%
Average body weight reduction in 68-week clinical trials
Weekly
Convenient injection frequency—no daily medication
85%+
Client satisfaction rate with tirzepatide therapy outcomes
$1,800
Average cost per month for tirzepatide therapy with medical oversight
Tirzepatide's dual-receptor mechanism produces superior weight loss compared to single-action GLP-1 agents. Clients typically see 1–2 lbs per week loss when combined with caloric deficit and lifestyle changes.
Tirzepatide signals satiety in the brain, naturally reducing hunger and food cravings. Many clients report decreased interest in high-calorie foods and smaller portion sizes without active willpower.
Beyond weight loss, tirzepatide improves insulin sensitivity, blood sugar control, and cardiovascular markers. Clients often see reductions in blood pressure, cholesterol, and inflammation.
Vivere's tirzepatide program includes baseline labs, ongoing vitals checks, medication interactions review, and dose titration under clinician guidance—reducing adverse events and optimizing outcomes.
Once-weekly injection fits easily into any schedule. No daily pills, complex meal plans, or time-intensive protocols—making long-term adherence realistic and sustainable.
Most clients see initial weight loss within 2–4 weeks, with momentum accelerating over 8–12 weeks. Peak weight loss typically occurs between 16–24 weeks. Results depend on adherence to caloric deficit, exercise, and dose consistency.
Most side effects are mild and transient: nausea, constipation, or reduced appetite (especially at initiation). Vivere's slow titration schedule minimizes GI upset. Severe side effects are rare; we monitor closely and adjust doses as needed.
Tirzepatide is designed for long-term use. Some clients maintain weight loss after discontinuation, while others experience gradual weight regain. Vivere's clinicians help you plan a maintenance strategy based on your individual response and goals.
Coverage varies by plan and medical indication. For weight loss in obesity without diabetes, many plans require prior authorization or don't cover it. Vivere can help verify your benefits and discuss cash-pay options and financing.
Ideal candidates include adults with BMI ≥30 or BMI ≥27 with weight-related conditions, realistic expectations, commitment to lifestyle changes, and no contraindications (pregnancy, personal/family history of thyroid cancer, pancreatitis). Vivere screens all candidates carefully.
Tirzepatide's dual GLP-1/GIP mechanism outperforms single-action GLP-1 agents (like semaglutide) in head-to-head trials, producing 20–30% greater weight loss. It's also more effective than older agents like phentermine or naltrexone/bupropion.
Complementary Service
Weight Management IV Therapy
Enhance tirzepatide results with IV hydration, nutrients, and metabolic support.
Wellness Support
Energy Drip
Maintain energy and stamina during active weight loss without relying on stimulants.
Related Therapy
Peptide Injections Near Me
Explore other injectable peptide therapies for metabolic and anti-aging benefits.
Schedule your consultation today.
Book a Session